MedTrace Logo

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

NCT04752865 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-01

No results posted yet for this study

Summary

EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN CANCER: TR\_NACT\_OV/17 In order to approach the above open questions, ultimately aiming in understanding the effects of cancer drugs on tumor biology and hence in selecting the proper drugs for the patients in the context of Precision Medicine, the objective of this study is to study the genomic characteristics of ovarian tumors before and after treatment with classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor olaparib.

Conditions

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Adamantia Nikolaidi · HECOG

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-09
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752865 on ClinicalTrials.gov